Skip to main content

Table 1 Details of scaffolds considered in the study and the cell lines against which their anticancer activity was reported along with the number of molecules in each cell lines and its molecular target/mechanism of action if studied.

From: Analogue-based approaches in anti-cancer compound modelling: the relevance of QSAR models

No. Scaffold name Cell lines Cancer type # of comp. Comments Ref.
S1 Naphthalimides LoVo Colon 23 DNA intercalators [31]
   A549 Lung 27   
   Hs468 Glioblastoma 23   
   U373-MG Glioblastoma 29   
   HCT-15 Colon 25   
   MCF-7 Breast 20   
S2 Aryl thiazolyl benzamide MB-231 Breast 27 Nek2 mitotic pathway [32]
   MB-468 Breast 25   
   K562 Blood 25   
S3 Procaspase activators U937 Lymphoma 19 Enhance procaspase-3 activity [33]
S4 Tylophorine analogues KB Nasopharyngeal 21 NF-kB signalling pathway [34]
   A549 Lung 21   
   DU-145 Prostate 21   
S5 Parthenin analogues HL-60 Blood 37 TopoisomeraseII inhibition [35]
   HeLa Cervical 37   
S6 Arylthiazolidine-4-acid amides A375 Melanoma 33 - [36]
   B16F1 Melanoma 33   
   DU-145 Prostate 32   
   LNCaP Prostate 35   
   PC-3 Prostate 31   
   PPC-1 Prostate 33   
   WM-164 Melanoma 32   
   Fibroblast Fibroblast 27   
   RH7777 Prostate 32   
S7 Hydroxyl benzofuranones LNCaP Prostate 22 Selective inhibitor of the mammalian target of rapamycin [37]
S8 Arylthiazole-4-acid amides B16F1 Melenoma 20 Tubulin polymerization inhibition [38]
   A375 Melanoma 20   
   DU-145 Prostate 16   
   PC-3 Prostate 17   
   LNCaP Prostate 17   
   PPC-1 Prostate 18   
S9 Estradiol 3,17-O,O-bis-sulfamates DU-145 Prostate 29 Disruption of the tubulin-microtubule equilibrium [39]
   MB-231 Breast 22   
S10 Aromathecins SF-539 CNS 29 Inhibitors of human topoisomerase I [40]
   HOP-62 Lung 28   
   HCT-116 Colon 28   
   UACC-62 Melanoma 27   
   SN12C Renal 26   
   MCF-7 Breast 29   
   DU-145 Prostate 23